<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992771</url>
  </required_header>
  <id_info>
    <org_study_id>8</org_study_id>
    <nct_id>NCT00992771</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3</brief_title>
  <official_title>A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Ataxia Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bob Allison Ataxia Research Center (BAARC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <brief_summary>
    <textblock>
      Spinocerebellar ataxia (SCA) is a group of inherited disorders characterized by cerebellar&#xD;
      degeneration leading to imbalance, incoordination, speech difficulties and problems with&#xD;
      walking. Recently, individual case reports have suggested that varenicline, a drug used in&#xD;
      smoking cessation, produces substantial improvement in patients with several inherited&#xD;
      ataxias. A modest response was noted in 5 patients with SCA, suggesting that it is&#xD;
      potentially efficacious in this disorder as well. Although this agent is available for&#xD;
      off-label use, the severe side effects noted with its use and the lack of long-term toxicity&#xD;
      data demand that it be systematically assessed. The present study will test whether&#xD;
      varenicline is safe and potentially efficacious in a heterogeneous cohort of adults with SCA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the patient's SARA Rating Scale total score</measure>
    <time_frame>25 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of dose-limiting adverse events</measure>
    <time_frame>25 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of varenicline on quality of life in patients with spinocerebellar ataxia</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of varenicline on depression and anxiety ratings</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of varenicline on the activity of daily living (ADL) in patients with spinocerebellar ataxia</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Spinocerebellar Ataxia Type 3</condition>
  <arm_group>
    <arm_group_label>Varneicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>up to 1mg BID for 8 weeks</description>
    <arm_group_label>Varneicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matching varenicline, up to 1mg BID for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatients with spinocerebellar ataxia type 3 diagnosed by a movement disorder&#xD;
             specialist and confirmed by genetic testing (of the patient or in a first degree&#xD;
             relative of the patient).&#xD;
&#xD;
          2. Age 18 years to 80 years.&#xD;
&#xD;
          3. Women of child-bearing potential must use a reliable method of contraception and must&#xD;
             provide a negative pregnancy test at entry into the study.&#xD;
&#xD;
          4. Serum creatine kinase, complete metabolic panel, complete blood count, liver function&#xD;
             tests, renal function tests, platelets and EKG are within normal limits (results&#xD;
             obtained from primary care physician and dated within the past 6 months or obtained at&#xD;
             screening visit).&#xD;
&#xD;
          5. Stable doses of all medications for 30 days prior to study entry and for the duration&#xD;
             of the study.&#xD;
&#xD;
          6. Ability to ambulate with or without assistance.&#xD;
&#xD;
          7. Score of 10 or higher (worse) on the SARA total score.&#xD;
&#xD;
          8. Score of 3 or higher (worse) on the 'gait' subsection of the SARA rating scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any unstable illness or concomitant medical condition that, in the investigator's&#xD;
             opinion, precludes participation in this study. This includes other disorders that may&#xD;
             affect gait or balance (stroke, arthritis, etc).&#xD;
&#xD;
          2. Pregnancy or lactation.&#xD;
&#xD;
          3. Concurrent participation in another clinical study.&#xD;
&#xD;
          4. Patients with a history of substance abuse.&#xD;
&#xD;
          5. Patients who currently smoke or have smoked within the past 12 months.&#xD;
&#xD;
          6. Presence of psychosis, bipolar disorder, untreated depression (BDI greater than or&#xD;
             equal to 21), or history of suicide attempt.&#xD;
&#xD;
          7. Concurrent treatment with any MAOIs, Wellbutrin, or nicotine patches.&#xD;
&#xD;
          8. Dementia or other psychiatric illness that prevents the patient from giving informed&#xD;
             consent (Mini Mental Status Exam score less than 24).&#xD;
&#xD;
          9. Legal incapacity or limited legal capacity.&#xD;
&#xD;
         10. Presence of severe renal disease (BUN 50% greater than normal or creatinine clearance&#xD;
             &lt;60 mL/min) or hepatic disease.&#xD;
&#xD;
         11. Abnormal creatine kinase and/or platelet count in the past 6 months (as determined by&#xD;
             lab reports obtained from primary care physicians or conducted at baseline).&#xD;
&#xD;
         12. Use of varenicline within the previous 30 days.&#xD;
&#xD;
         13. Ataxia derived from any other cause than genetically-confirmed SCA (including but not&#xD;
             limited to alcoholism, head injury, Multiple Sclerosis, olivo-ponto-cerebellar atrophy&#xD;
             or multiple system atrophy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Zesiewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Theresa Zesiewicz</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 23, 2012</submitted>
    <returned>August 24, 2012</returned>
    <submitted>December 7, 2012</submitted>
    <returned>January 14, 2013</returned>
    <submitted>January 15, 2013</submitted>
    <returned>February 14, 2013</returned>
    <submitted>December 15, 2014</submitted>
    <returned>December 24, 2014</returned>
    <submitted>April 7, 2018</submitted>
    <returned>May 4, 2018</returned>
    <submitted>November 8, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

